IgniteIt · Cannabis Capital ConferenceMIAMI 2027March 24–26 · The Diplomat Beach Resort, Hollywood FL
The story behind the story.
Village Farms Builds. Vireo Buys. Who Keeps the Cash?
Cannabis companies are expanding again. But not everyone is paying for growth the same way.
Some are investing in production capacity they already control. Others are acquiring businesses, taking on debt, and issuing shares to assemble larger platforms.
Both strategies can increase revenue. Whether they create value for shareholders is another question.
This week, Rolando García Bernado, PhD, IgniteIt’s Chief Economic Columnist, compares Village Farms International and Vireo Growth to examine what their financial statements reveal about the cost of expansion.
We’re also looking at Organigram’s push to capture more of the European supply chain, Cronos’ international growth, SNDL’s capital allocation decisions, and a new Dickinson Wright analysis of cannabis patents.
And with a new DEA procedural deadline approaching, the federal policy debate remains very much on the agenda.
— Nico Rodriguez, Managing Editor
Nov. 18 in Washington, D.C.Cannabis Capital & Policy Summit, Grand Hyatt Washington — join us
One Date
Oct. 21
The DEA faces an October 21 deadline to respond to a motion seeking additional testimony and discovery in the cannabis rescheduling proceedings.
The administrative hearing remains stayed. The deadline is procedural, not a decision on rescheduling itself.
Financial forecasts increasingly incorporate assumptions about federal reform, but the administrative and judicial processes remain separate.
The Big Story
Village Farms Builds. Vireo Buys. Which Strategy Produces Better Returns?
Revenue growth can come from selling more cannabis, expanding into new markets, or buying companies that already generate sales.
But those strategies have different consequences for capital expenditures, debt, dilution, and cash flow.
In a new IgniteIt analysis, Rolando García compares Village Farms International (NASDAQ: VFF) with Vireo Growth (CSE: VREO; OTCQX: VREOF).
Village Farms is expanding through its existing greenhouse infrastructure, converting capacity and finding new customers for production it can already support.
Vireo has pursued a different path, assembling a larger cannabis platform through acquisitions.
Two companies, two growth rates
Village Farms reported 5% cannabis revenue growth in the second quarter of 2026, with an adjusted EBITDA margin of 28.5%, up from 25.8%.
Vireo reported revenue growth of 265.5%, largely driven by acquisitions. Its adjusted EBITDA margin declined from 27.7% to 22.4%.
On the surface, Vireo is growing much faster.
But the comparison changes when we examine what each company had to spend, borrow, or issue to produce that growth.
The acquisition bill
Buying an operating business can provide immediate revenue, market access, and production capacity.
It can also bring inherited liabilities, integration expenses, additional debt, and dilution for existing shareholders.
Village Farms’ model avoids some acquisition costs by expanding within infrastructure it already owns. That does not make expansion free, but it changes the capital required to generate incremental sales.
Vireo’s strategy offers a different opportunity: acquiring established operations and improving their performance within a larger organization.
The challenge is proving that the acquired earnings justify the purchase price and financing structure.
What the cash-flow statements reveal
Rolando examines both companies beyond their headline revenue and adjusted EBITDA figures, including the implications of debt, share issuance, and Section 280E.
The comparison also draws on the experience of Schwazze, whose acquisition-driven expansion illustrates the risks of building a large platform without generating sufficient financial returns.
How much cash can the business generate after paying for that growth, and how much of the resulting value belongs to each shareholder?
Read Rolando’s full Village Farms–Vireo analysisA question for the C-suite
If you were allocating capital today, would you rather acquire an established cannabis operation or expand capacity inside a business you already control?
Email the desk. We’d like to hear how operators and investors are evaluating that decision.
Are you a cannabis CEO, CFO, or senior executive with a perspective on capital allocation, profitability, or industry consolidation? Email us to contribute to our reporting or arrange an interview with IgniteIt’s editorial team.
The Other Side of Growth
Organigram Wants the Entire Margin
In an exclusive IgniteIt interview, Sanity Group co-founder Finn Hänsel explained the economics behind Organigram’s European expansion.
Sanity Group expects approximately €120 million in 2026 revenue, compared with €60 million in 2025.
But the larger strategic question is where those revenues — and their associated margins — are generated.
Through the Sanity acquisition, Organigram is seeking greater control over the European cannabis supply chain, from production to distribution through German pharmacies. That strategy differs from simply exporting more cannabis.
By controlling additional stages of the business, Organigram aims to capture margins that would otherwise accrue to intermediaries. Of course, owning more of the supply chain also means taking responsibility for more of its operating costs and regulatory obligations.
The investment case depends on whether the additional margin exceeds the capital required to capture it.
Read our exclusive Organigram–Sanity interview →
Cronos: What Does a Cash-Rich Expansion Look Like?
Cronos reported second-quarter revenue of approximately $53 million, up 58%, while its international exports outside Israel increased 88%. Canadian market share reached 6.1%.
The company’s substantial liquidity provides flexibility to pursue acquisitions, expand distribution, and invest in its brands without relying exclusively on external financing.
Zuanic & Associates has highlighted approximately $827 million in cash, deposits, and investments as a central element of the Cronos investment thesis.
The Capital Test
SNDL: Buy Back Shares or Buy More Cannabis Assets?
SNDL is considering a C$50 million tender offer following shareholders’ rejection of a proposed reverse stock split.
The company has also been increasing its exposure to U.S. cannabis through Parallel, with its economic interest expected to reach 92%.
Management expects C$20 million in quarterly free cash flow, although C$10.6 million of the recently reported amount came from an insurance-related transaction. That distinction matters when evaluating how much cash is available for recurring distributions or reinvestment.
SNDL’s decisions put two competing uses of capital into focus. A buyback can increase each remaining shareholder’s ownership percentage. Acquisitions and expansion can increase the size of the underlying business.
Neither creates value automatically. The relevant comparison is the return management expects from buying back its own shares versus investing the same money elsewhere.
The SpreadWeek 6 of 11
Aurora Says No to Curaleaf’s $5 Offer
Curaleaf increased its hostile bid for Aurora Cannabis from $4 to $5 per share. Aurora’s board has again recommended that shareholders reject the revised proposal.
The company argues that the offer undervalues its assets, exposes shareholders to Curaleaf share-price risk, and relies on projected synergies that have not been sufficiently substantiated.
Curaleaf, meanwhile, sees an opportunity to combine international medical cannabis operations and generate efficiencies from a larger platform.
The revised offer has not resolved the central disagreement: how much Aurora is worth independently, and how much of the potential value from a combination should accrue to its existing shareholders. The offer expires December 4.
Curaleaf / AuroraAs of Oct. 16 close
3.7%Aurora’s discount
to offer value
to offer value
Aurora closed at $3.99 against consideration worth $4.14. A week earlier the gap was 5.3%.
32%Annualized return
if it closes
if it closes
$4.14Offer’s value,
down from $4.53
down from $4.53
44Days until
Dec. 4 expiry
Dec. 4 expiry
Why it matters: Aurora’s board is rejecting $5. The market isn’t pricing $5. Most of the bid is paid in Curaleaf shares, which fell another 11% last week, so the offer was worth $4.14 at Friday’s close, down from $5.01 two weeks ago. Aurora fell too, to $3.99. The gap is now the narrowest since we started tracking it, which usually means the market sees better odds of a deal closing, at whatever Curaleaf’s stock is worth on the day.
The question this week:
If Aurora’s shareholders reject $5, what price — or alternative transaction — would justify changing their minds?
DW Analysis
Cannabis Patents Are Already Valuable. They Can Also Become Expensive Liabilities.
When a cannabis company acquires a cultivation facility, a processing business, or a genetics portfolio, what exactly is it buying? The physical assets and existing revenue are only part of the answer.
In a Dickinson Wright client alert, attorneys J. Morgan Dixon and Jonathan R. Wachs examine how changing marijuana laws affect patents covering cannabis plants, seeds, genetics, and processing technologies.
Their central point is that cannabis patents have existed for years, despite federal restrictions on commercial marijuana activity.
Unlike federal trademarks, which generally depend on lawful commercial use, patents can protect qualifying inventions even when using those inventions remains restricted under another body of law.
A patent gives its owner the right to exclude others from practicing the protected invention. It does not automatically give the owner permission to practice it.
What operators may already own
A cannabis business may have protectable innovations in cultivation techniques, extraction processes, formulation chemistry, equipment, or plant genetics. Those rights can support licensing agreements, strategic partnerships, and acquisition valuations.
But an operator may also be using technology covered by someone else’s patent. Dickinson Wright warns that federal illegality does not necessarily prevent patent owners from pursuing infringement claims.
What investors should examine
The attorneys emphasize claim scope, evidence of earlier inventions or practices, the quality of technical disclosures, and the practical ability to enforce the rights.
Some older cannabis patents may appear broad because prohibition limited the documentation of prior innovations. That can make a portfolio look valuable on paper while leaving it vulnerable to legal challenges.
And delaying patent filings until federal law changes can mean losing rights through earlier public disclosures or competing applications.
Based on Dickinson Wright’s client alert, “Cannabis Patents: How Evolving Marijuana Laws Affect Plant, Seed, and Processing Innovation,” by J. Morgan Dixon and Jonathan R. Wachs.
Signal
Glass House Looks Toward Europe
Glass House Brands received Good Agricultural and Collection Practice certification for two California cultivation facilities covering more than 500,000 square feet.
GACP certification can help establish the agricultural standards required by European medical cannabis supply chains, although it does not itself authorize international exports.
The commercial opportunity is potentially significant: access to additional buyers and markets beyond California’s highly competitive domestic environment.
The remaining questions involve regulatory approvals, distribution arrangements, processing requirements, and the economics of getting the product to European customers.
The Bottom Line
Revenue Is Not the Same as Shareholder Value
Village Farms is expanding from infrastructure it already controls. Vireo is acquiring operating businesses. Organigram wants a larger share of Europe’s cannabis margins. Cronos has substantial capital available for expansion. SNDL is weighing shareholder distributions against additional investment.
Different companies, different strategies. But they all face the same financial test.
Can management generate enough cash from the capital it deploys to justify the risks, financing costs, and ownership dilution involved?
A company can double its revenue and still leave shareholders worse off. It can also grow slowly and create substantial value by improving margins and generating cash without continually issuing shares or borrowing.
The real question isn’t how quickly a cannabis company can grow. It’s what existing shareholders get to keep after the growth is paid for.
Which expansion strategy looks most attractive in today’s market?
From California to Washington
November 18 · Washington, D.C.
Next Stop: Washington, D.C.
Thank you again to everyone who joined us at IgniteIt California.
Our next event brings the conversation to the nation’s capital, where federal cannabis policy, investment decisions, taxation, and access to capital will take center stage.
IgniteIt Cannabis Capital & Policy Summit
November 18, 2026 · Washington, D.C.
Join cannabis executives, investors, policymakers, and financial professionals to discuss the business decisions shaping the industry’s future.
Join us at IgniteIt Washington, D.C.Upcoming IgniteIt Events
Cannabis Capital & Policy SummitNov 18 · Washington, D.C.